ResVerlogiX

Focus: ResVerlogiX is a public-stage small molecule biotech founded in 2001, headquartered in Calgary, focused on cardiovascular, metabolic, infectious disease, nephrology, and rare disease therapeutics. The company operates as a mid-cap biotech with a diversified pipeline across multiple therapeutic areas.

Cardiovascular Metabolic Diseases Infectious Diseases Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About ResVerlogiX

AI assessmentNot Hiring

No open roles listed right now. Follow ResVerlogiX to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Apabetalone

Pulmonary Arterial Hypertension

PHASE_1

Clinical Trials (1)

NCT03655704Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

Phase 1

Help build intelligence for ResVerlogiX

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline with 13 active programs across five therapeutic areas including high-unmet-need indications like post-acute COVID-19 and PAH
Two lead compounds (Apabetalone and RVX000222) with multiple Phase 2-3 programs providing multiple clinical catalysts over next 2-3 years
Rare disease and nephrology focus offers opportunity to contribute to underserved patient populations with meaningful clinical impact

Watch Out For

Zero active job openings and no disclosed hiring activity suggests limited near-term career entry points or expansion
No commercial products, publications, or public financial data creates visibility gap on company trajectory, cash runway, and strategic direction
Early-stage pipeline (11 Phase 2, only 3 Phase 3 programs) with long development timeline ahead before potential revenues or market success

Generated by Claude from ResVerlogiX's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

apabetalone

Kidney Failure, Chronic

PHASE_1_2

Clinical Trials (1)

NCT03160430A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Phase 1/2

RVX000222

Dyslipidemia

PHASE_1_2

Clinical Trials (1)

NCT00768274Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Phase 1/2